Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JIGAR SHAH

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1659508166
CMS profile
347688
Location
MARGATE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$60,386.34

130 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 3; records 101–130 of 130 matching records. This page contains 30 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JIGAR SHAH

NPI 1659508166 · CMS profile ID 347688

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

MARGATE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–130 of 130 matching records. This page contains 30 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1659508166?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JIGAR SHAH, NPI 1659508166, CMS profile ID 347688. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–130 of 130 matching records. This page contains 30 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1659508166?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JIGAR SHAH, NPI 1659508166, CMS profile ID 347688. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–130 of 130 matching records. This page contains 30 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1659508166?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JIGAR SHAH, NPI 1659508166, CMS profile ID 347688, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–130 of 130 matching records. This page contains 30 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1659508166?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

130 matching records · $60,386.34 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 130 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–130 of 130.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $0.8004/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796011329 CMS
AbbVie Inc. $5.3204/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796011331 CMS
GlaxoSmithKline, LLC. $3,600.0004/07/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802868575 CMS
Horizon Therapeutics plc $200.0004/05/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797204785 CMS
Teva Pharmaceuticals USA, Inc. $17.0104/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839636367 CMS
Horizon Therapeutics plc $1,020.0003/31/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797204783 CMS
GlaxoSmithKline, LLC. $125.0003/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802877237 CMS
Amgen Inc. $20.7503/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825417287 CMS
AbbVie Inc. $10.9403/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796011327 CMS
GlaxoSmithKline, LLC. $1,200.0003/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802990257 CMS
PFIZER INC. $23.7003/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832651521 CMS
UCB, Inc. $27.9703/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807304335 CMS
Horizon Therapeutics plc $8.2802/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797204779 CMS
GlaxoSmithKline, LLC. $13.9602/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802220935 CMS
GlaxoSmithKline, LLC. $3,600.0002/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802884509 CMS
Horizon Therapeutics plc $1,020.0002/13/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797204777 CMS
UCB, Inc. $17.3002/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807307185 CMS
Horizon Therapeutics plc $1,020.0002/08/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797204773 CMS
GlaxoSmithKline, LLC. $1,200.0002/04/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801658631 CMS
Horizon Therapeutics plc $1,020.0002/04/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797204771 CMS
PFIZER INC. $24.8002/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832594111 CMS
PFIZER INC. $7.7302/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832851329 CMS
Amgen Inc. $21.4001/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825417269 CMS
GlaxoSmithKline, LLC. $125.0001/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802891397 CMS
Novartis Pharmaceuticals Corporation $36.2001/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813249251 CMS
Horizon Therapeutics plc $1.0001/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797204765 CMS
Horizon Therapeutics plc $7.1601/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797204767 CMS
PFIZER INC. $19.5301/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832729853 CMS
GlaxoSmithKline, LLC. $1,800.0001/12/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803037543 CMS
AbbVie Inc. $23.6701/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796011325 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $42,178.78 168
PY2020 $21,731.51 82
PY2021 $60,386.34 130
PY2022 $128,057.91 206
PY2023 $116,590.97 223
PY2024 $165,951.74 283
PY2025 $214,842.62 350

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,296,842.30 71
PY2024 Recipient $27,504.58 2
PY2024 Principal investigator $995,618.72 76
PY2023 Principal investigator $495,317.67 93
PY2022 Principal investigator $548,956.32 82
PY2021 Recipient $140.90 1
PY2021 Principal investigator $420,026.19 24
PY2020 Recipient $777.04 1
PY2020 Principal investigator $55,128.00 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

71 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $7,575.00 12/11/2025 Non-covered Recipient Entity
CORAZON USA LLC
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren s Disease (SjD) No dispute reported 06/30/2026 1202530126
Principal investigator 1 ABBVIE INC. $6,885.55 12/08/2025 Non-covered Recipient Entity
CORAZON USA LLC
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren s Disease (SjD) No dispute reported 06/30/2026 1202529640
Principal investigator 1 UCB SA $16,250.00 12/08/2025 Non-covered Recipient Entity
CORAZON USA LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246658254
Principal investigator 1 ABBVIE INC. $2,640.00 12/04/2025 Non-covered Recipient Entity
CORAZON USA LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202527976
Principal investigator 1 ABBVIE INC. $12,039.50 12/04/2025 Non-covered Recipient Entity
CORAZON USA LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202528786
Principal investigator 1 ABBVIE INC. $989.51 12/04/2025 Non-covered Recipient Entity
CORAZON USA LLC
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202528806
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,500.00 12/03/2025 Non-covered Recipient Entity
Corazon USA LLC
INSPIRE LTE study No dispute reported 06/30/2026 1246431278
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,212.57 11/19/2025 Non-covered Recipient Entity
Corazon USA LLC
INSPIRE LTE study No dispute reported 06/30/2026 1246431272
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $240.61 11/19/2025 Non-covered Recipient Entity
Corazon USA LLC
INSPIRE LTE study No dispute reported 06/30/2026 1246431282
Principal investigator 1 ABBVIE INC. $75.00 11/05/2025 Non-covered Recipient Entity
CORAZON USA LLC
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202522195
Principal investigator 1 ABBVIE INC. $6,536.25 11/04/2025 Non-covered Recipient Entity
CORAZON USA LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202520549
Principal investigator 1 ABBVIE INC. $47,527.50 11/04/2025 Non-covered Recipient Entity
CORAZON USA LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202520551
Principal investigator 1 ARGENX US, INC. $3,000.00 10/22/2025 Non-covered Recipient Entity
CORAZON USA LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149253
Principal investigator 1 ARGENX US, INC. $3,000.00 10/22/2025 Non-covered Recipient Entity
CORAZON USA LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149259
Principal investigator 1 ARGENX US, INC. $1,250.00 10/22/2025 Non-covered Recipient Entity
CORAZON USA LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149264
Principal investigator 1 ARGENX US, INC. $2,200.00 10/22/2025 Non-covered Recipient Entity
CORAZON USA LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149269
Principal investigator 1 ARGENX US, INC. $2,000.00 10/22/2025 Non-covered Recipient Entity
CORAZON USA LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149273
Principal investigator 1 ARGENX US, INC. $16,000.00 10/22/2025 Non-covered Recipient Entity
CORAZON USA LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149278
Principal investigator 1 ARGENX US, INC. $1,500.00 10/22/2025 Non-covered Recipient Entity
CORAZON USA LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149283
Principal investigator 1 Amgen Inc. $20,497.66 10/22/2025 Non-covered Recipient Entity
CORAZON USA, LLC
A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis No dispute reported 06/30/2026 1246640525
Principal investigator 1 ABBVIE INC. $10,323.75 10/09/2025 Non-covered Recipient Entity
CORAZON USA LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202515327
Principal investigator 1 Aurinia Pharma U.S., Inc. $6,600.00 10/08/2025 Non-covered Recipient Entity
Corazon USA, LLC
LUPKYNIS Registry Study No dispute reported 06/30/2026 1243931074
Principal investigator 1 GENZYME CORPORATION $28,921.00 10/06/2025 Non-covered Recipient Entity
Corazon Usa Llc Dba Life Clinical Trials
A randomized, double-blind, Phase 3, 52-week study to evaluate the efficacy and safety of rilzabrutinib (SAR444671) compared to placebo in adult participants with active iGG4-related disease. No dispute reported 06/30/2026 1226140114
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,259.84 10/02/2025 Non-covered Recipient Entity
Corazon USA LLC
INSPIRE LTE study No dispute reported 06/30/2026 1246431276
Principal investigator 1 ABBVIE INC. $2,640.00 09/03/2025 Non-covered Recipient Entity
CORAZON USA LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202507169
Principal investigator 1 ARGENX US, INC. $35.80 09/03/2025 Non-covered Recipient Entity
CORAZON USA LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149286
Principal investigator 1 ARGENX US, INC. $668.50 09/03/2025 Non-covered Recipient Entity
CORAZON USA LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149290
Principal investigator 1 ARGENX US, INC. $159.00 09/03/2025 Non-covered Recipient Entity
CORAZON USA LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149294
Principal investigator 1 ARGENX US, INC. $6.65 09/03/2025 Non-covered Recipient Entity
CORAZON USA LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149300
Principal investigator 1 ARGENX US, INC. $103.50 09/03/2025 Non-covered Recipient Entity
CORAZON USA LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149304
Principal investigator 1 ARGENX US, INC. $75.20 09/03/2025 Non-covered Recipient Entity
CORAZON USA LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149307
Principal investigator 1 Amgen Inc. $333.35 08/26/2025 Non-covered Recipient Entity
LIFE CLINICAL TRIALS
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246643562
Principal investigator 1 AstraZeneca Pharmaceuticals LP $19,735.00 08/06/2025 Non-covered Recipient Entity
CORAZON USA, LLC
A Multicenter,Randomized,Double blind,Placebo controlled,Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Systemic Sclerosis No dispute reported 06/30/2026 1185544605
Principal investigator 1 ABBVIE INC. $12,660.00 08/05/2025 Non-covered Recipient Entity
CORAZON USA LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202501178
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $21,297.33 07/25/2025 Non-covered Recipient Entity
KERLO RESEARCH
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246433209
Principal investigator 1 AstraZeneca Pharmaceuticals LP $19,735.00 07/23/2025 Non-covered Recipient Entity
CORAZON USA, LLC
A Multicenter, Parallel-group, Double-blind, 2-Arm, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared with Placebo Added to Standard of Care in Adult Participants with Polymyositis No dispute reported 06/30/2026 1185544607
Principal investigator 1 Eli Lilly and Company $25,604.00 07/23/2025 Non-covered Recipient Entity
CORAZON USA LLC
A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187878827
Principal investigator 1 ABBVIE INC. $44,695.00 07/02/2025 Non-covered Recipient Entity
CORAZON USA LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202496575
Principal investigator 1 ABBVIE INC. $23,145.00 07/02/2025 Non-covered Recipient Entity
CORAZON USA LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202496577
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $7,082.10 07/02/2025 Non-covered Recipient Entity
KERLO RESEARCH
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246433198
Principal investigator 1 ABBVIE INC. $17,000.00 06/25/2025 Non-covered Recipient Entity
CORAZON USA LLC
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202492845
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,212.57 06/25/2025 Non-covered Recipient Entity
Corazon USA LLC
INSPIRE LTE study No dispute reported 06/30/2026 1246431270
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,950.00 06/17/2025 Non-covered Recipient Entity
CORAZON USA LLC
A Two-year, Phase III Randomized, Double-blind, Parallel-group, Placebo-controlled Trial to Evaluate the Safety, Efficacy, and Tolerability of 300 mg s.c. Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis No dispute reported 06/30/2026 1190311205
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,905.12 06/11/2025 Non-covered Recipient Entity
KERLO RESEARCH
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246433236
Principal investigator 1 ABBVIE INC. $12,795.00 06/03/2025 Non-covered Recipient Entity
CORAZON USA LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202488313
Principal investigator 1 ABBVIE INC. $100.00 06/03/2025 Non-covered Recipient Entity
CORAZON USA LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202488317
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $8,250.00 06/02/2025 Non-covered Recipient Entity
KERLO RESEARCH
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246433245
Principal investigator 1 ABBVIE INC. $20,160.00 05/06/2025 Non-covered Recipient Entity
CORAZON USA LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202482073
Principal investigator 1 Amgen Inc. $112,510.66 04/28/2025 Non-covered Recipient Entity
CORAZON USA, LLC
A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants No dispute reported 06/30/2026 1246640527
Principal investigator 1 Eli Lilly and Company $21,262.00 04/28/2025 Non-covered Recipient Entity
CORAZON USA LLC
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187878517
Principal investigator 1 ABBVIE INC. $433.17 04/08/2025 Non-covered Recipient Entity
CORAZON USA LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202474969
Principal investigator 1 ABBVIE INC. $3,787.50 04/03/2025 Non-covered Recipient Entity
CORAZON USA LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202469978
Principal investigator 1 ABBVIE INC. $5,662.00 04/03/2025 Non-covered Recipient Entity
CORAZON USA LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202473735
Principal investigator 1 Aurinia Pharma U.S., Inc. $1,755.00 03/26/2025 Non-covered Recipient Entity
Corazon USA, LLC
LUPKYNIS Registry Study No dispute reported 06/30/2026 1243931064
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,462.69 03/14/2025 Non-covered Recipient Entity
KERLO RESEARCH
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246433217
Principal investigator 1 Aurinia Pharma U.S., Inc. $2,632.50 03/12/2025 Non-covered Recipient Entity
Corazon USA, LLC
LUPKYNIS Registry Study No dispute reported 06/30/2026 1243930900
Principal investigator 1 ABBVIE INC. $14,988.75 03/07/2025 Non-covered Recipient Entity
CORAZON USA LLC
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202459671
Principal investigator 1 ABBVIE INC. $4,910.00 03/06/2025 Non-covered Recipient Entity
CORAZON USA LLC
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202456789
Principal investigator 1 Eli Lilly and Company $4,250.00 03/05/2025 Non-covered Recipient Entity
CORAZON USA LLC
TALTZ PSA OBSERVATIONAL STUDY No dispute reported 06/30/2026 1187878749
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $172.08 03/05/2025 Non-covered Recipient Entity
Corazon USA LLC
INSPIRE LTE study No dispute reported 06/30/2026 1246431280
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,733.69 03/03/2025 Non-covered Recipient Entity
Corazon USA LLC
INSPIRE LTE study No dispute reported 06/30/2026 1246431274
Principal investigator 1 ABBVIE INC. $21,504.50 02/06/2025 Non-covered Recipient Entity
CORAZON USA LLC
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202449777
Principal investigator 1 ABBVIE INC. $11,876.25 02/06/2025 Non-covered Recipient Entity
CORAZON USA LLC
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202449781
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,708.18 02/05/2025 Non-covered Recipient Entity
KERLO RESEARCH
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246433222
Principal investigator 1 SANOFI US SERVICES INC. $29,600.00 02/04/2025 Non-covered Recipient Entity
Corazon Usa Llc Dba Life Clinical Trials
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226139968
Principal investigator 1 Eli Lilly and Company $2,540.34 01/23/2025 Non-covered Recipient Entity
CORAZON USA LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187880377
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $38,279.65 01/21/2025 Non-covered Recipient Entity
Life Clinical Trials
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (POETYK SLE-2) No dispute reported 06/30/2026 1235996189
Principal investigator 1 Eli Lilly and Company $123,618.00 01/21/2025 Non-covered Recipient Entity
CORAZON USA LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187881416
Principal investigator 1 Amgen Inc. $1,413,938.48 01/13/2025 Non-covered Recipient Entity
LIFE CLINICAL TRIALS
A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants No dispute reported 06/30/2026 1246643570
Principal investigator 1 Amgen Inc. $23,340.00 01/03/2025 Non-covered Recipient Entity
LIFE CLINICAL TRIALS
A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis No dispute reported 06/30/2026 1246643566
Principal investigator 1 ABBVIE INC. $2,505.00 01/02/2025 Non-covered Recipient Entity
CORAZON USA LLC
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202436118